News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Contraindicated Enoxaparin, Eptifibatide Linked with Increased Risk for Bleeding, Mortality in Dialysis Patients Undergoing PCI
January 5, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Cardiology Today -- The receipt of contraindicated antithrombotic medications after percutaneous coronary intervention was associated with an increased risk for bleeding and death in patients undergoing dialysis, study results suggested.
Twitter
LinkedIn
Facebook
Email
Print